OP0048 Romosozumab rapidly reduces clinical vertebral fracture incidence: results from the frame study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.5796
Abstract: Background Romosozumab (ROMO) inhibits sclerostin and has a dual effect on bone, increasing formation while decreasing resorption, resulting in significant increases in bone mineral density (BMD) at 6 months (m), which at 12m reach 13.3%… read more here.
Keywords: research; clin vfx; amgen; romo ... See more keywords